Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease | Zendy

Gina Patel | Zendy; Parameswaran Hari | Zendy; Anikó Szabó | Zendy; Lisa Rein | Zendy; Lisa Baumann Kreuziger | Zendy; Saurabh Chhabra | Zendy; Binod Dhakal | Zendy; Anita D’Souza | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease

Author(s) -

Gina Patel,

Parameswaran Hari,

Anikó Szabó,

Lisa Rein,

Lisa Baumann Kreuziger,

Saurabh Chhabra,

Binod Dhakal,

Anita D’Souza

Publication year - 2018

Publication title -

hematology/oncology and stem cell therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.666

H-Index - 22

eISSN - 1658-3876

pISSN - 2589-0646

DOI - 10.1016/j.hemonc.2018.05.002

Subject(s) - amyloidosis , al amyloidosis , immunoglobulin light chain , disease , medicine , chain (unit) , factor (programming language) , dermatology , pathology , immunology , computer science , physics , quantum mechanics , antibody , programming language

Systemic light chain (AL) amyloidosis can lead to an acquired coagulopathy secondary to acquired factor X (aFX) deficiency. However, it is not very clear who develops aFX deficiency in AL amyloidosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research